63
Participants
Start Date
October 31, 2013
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
Pirfenidone
Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
Hospital for Special Surgery, New York
Columbia University, New York
Università di Torino, Orbassano
University of Pittsburgh Medical Center, Pittsburgh
Georgetown University Hospital, Washington D.C.
Medical University South Carolina, Charleston
University of Toledo, Toledo
Cleveland Clinic Foundation, Cleveland
University of Cincinnati, Cincinnati
University of Michigan, Ann Arbor
University of Florence, Florence
Northwestern University, Chicago, Chicago
University of Texas, Houston, Houston
National Jewish Medical and Research Center, Denver
University of Utah, Salt Lake City
Mayo Clinic, Scottsdale, Scottsdale
University of California, Los Angeles, Los Angeles
Stanford University School of Medicine, Redwood City
University of California, San Francisco, San Francisco
Boston University Medical Center, Boston
St. Joseph's Healthcare, Hamilton
Toronto General Hospital, Toronto
Lead Sponsor
Genentech, Inc.
INDUSTRY